Note to Affiliate: This document is based on the November 2023 Irish SmPC, the August 2020 J Tube IFU, the March 2019 NJ Tube IFU, the August 2020 PEG IFU, the 2019 CADD Duodopa Patient Information Guide, and the February 2019 CADD Duodopa Pump Operator's Manual.
Duodopa (levodopa/carbidopa intestinal gel) is for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results1
People in this piece are models, not actual patients.
People in this piece are models, not actual patients.
Duodopa (levodopa/carbidopa intestinal gel) is for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results1
People in this piece are models, not actual patients.
Because ON TIME is their time
EXPERT PERSPECTIVES
Movement Disorder Specialists share their experience of and views on Duodopa for the treatment of patients with advanced Parkinson’s disease
I want to receive more information via a product specialist
References
- Duodopa (levodopa/carbidopa intestinal gel) SmPC; [insert current data]